Propranolol: A migraine prophylactic since the 1960s
DOI:
https://doi.org/10.48208/HeadacheMed.2023.2Keywords:
Beta-blocker, Propranolol, Migraine, ProphylaxisAbstract
Introduction
Propranolol was the first non-selective beta-adrenergic blocker to be developed. Initially it was used in the treatment of cardiovascular diseases, but since the 60's it has been used in the prevention of migraine.
Objective
The objective of this study was to know the history of propranolol and its use as a migraine prophylactic.
Methods
This study was an integrative literature review using articles with historical data on propranolol, from its origin in cardiology to its indication in the preventive treatment of migraine.
Results
Propranolol was described in 1962 for the treatment of cardiovascular diseases. In the same decade, it was prescribed for the preventive treatment of migraine and, recently, included in the consensus of the Brazilian Headache Society.
Conclusion
Although propranolol was initially synthesized for the treatment of heart disease, it has proved to be an effective drug in preventing migraine attacks.
Downloads
References
Black JW and Stephenson JS. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet 1962;2(7251):311-314 Doi:10.1016/s0140-6736(62)90103-4. DOI: https://doi.org/10.1016/S0140-6736(62)90103-4
Black O, Gerskowitch SV, Hull RA and Shankley NP. The pharmacological toolmaker's rational approach to drug design: An appreciation of Sir James Black. Trends Pharmacol Sci 1988;9:435-437 Doi:10.1016/0165-6147(88)90132-0. DOI: https://doi.org/10.1016/0165-6147(88)90132-0
Stapleton MP. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology. Tex Heart Inst J 1997;24(4):336-342.
Srinivasan AV. Propranolol: A 50-year historical perspective. Ann Indian Acad Neurol 2019;22(1):21-26 Doi:10.4103/aian.AIAN_201_18. DOI: https://doi.org/10.4103/aian.AIAN_201_18
Dornhorst AC and Robinson BF. Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide). Lancet 1962;2(7251):314-316 Doi:10.1016/s0140-6736(62)90104-6. DOI: https://doi.org/10.1016/S0140-6736(62)90104-6
Prichard BN. Propranolol in the treatment of angina: a review. Postgrad Med J 1976;52(Suppl 4):35-41.
Lambert DM. Effect of propranolol on mortality in patients with angina. Postgrad Med J 1976;52(Suppl 4):57-60.
Rabkin R, Stables DP, Levin NW and Suzman MM. The prophylactic value of propranolol in angina pectoris. Am J Cardiol 1966;18:370-383. DOI: https://doi.org/10.1016/0002-9149(66)90056-7
Silva-Néto RP, Barbosa JMS and Almeida K. Analysis of the package inserts of migraine prophylactics. Headache Medicine 2010;1(1):12-16. DOI: https://doi.org/10.48208/HeadacheMed.2010.4
Fitzgerald JD. Beta-blockade and mechanisms of disease. Postgrad Med J 1976;52(Suppl 4):184-190.
Ganellin R and Duncan W. Obituary: James Black (1924–2010). Nature 2010;464:1292 Doi:10.1038/4641292a. DOI: https://doi.org/10.1038/4641292a
Silva-Néto RP. Quem foi Edgard Raffaelli Júnior. Migrâneas cefaléias 2006;9(4):152-158.
Silva-Néto RP. The study of headache in the 1950s in Latin America by Edgard Raffaelli Júnior (1930-2006). Headache 2015;55(5):713-717 Doi:10.1111/head.12578. DOI: https://doi.org/10.1111/head.12578
Sicuteri F. Prophylactic and therapeutic properties of 1-methyllysergic acid butanolamide in migraine. Int Arch Allergy 1959;15:300-307 Doi:10.1159/000229055. DOI: https://doi.org/10.1159/000229055
Brasilian Headache Society. Recommendations for prophylactic treatment of migraine: Consensus of the Sociedade Brasileira de Cefaléia. Arq Neuropsiquiatr 2002;60(1):159-169 Doi:10.1590/s0004-282x2002000100030. DOI: https://doi.org/10.1590/S0004-282X2002000100030
Santos PSF, Melhado EM, Kaup AO, Costa ATNM, Roesler CAP,Piovesan EJ, and ... Fragoso YD. Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II. Arq Neuropsiquiatr 2022;80(9):953-969 Doi:10.1055/s-0042-1755320. DOI: https://doi.org/10.1055/s-0042-1755320
Danesh A, Gottschalk PCH. Beta-blockers for migraine prevention: A review article. Curr Treat Options Neurol 2019;21(4):20 Doi:10.1007/s11940-019-0556-3. DOI: https://doi.org/10.1007/s11940-019-0556-3
Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004;8(2):91-95 Doi:10.1007/s11916-004-0022-z. DOI: https://doi.org/10.1007/s11916-004-0022-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Wallyson Pablo de Oliveira Souza, Yasmine Maria Leódido Fortes, Adriana de Almeida Soares, Raimundo Pereira Silva-Néto
This work is licensed under a Creative Commons Attribution 4.0 International License.